Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
Lupus. 2010 Oct;19(12):1468-73. doi: 10.1177/0961203310370051.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiorgan involvement and high mortality, which was reduced because of the most widely and classically used immunosuppressive therapies. However, some patients continue to have significant mortality. So a shift in the approach to the treatment of SLE is needed. In the past decade, most transplants have been performed in the treatment of SLE with allogeneic or autologous hematopoietic stem cells and currently emerging mesenchymal stem cells. There are some important differences between the two procedures.
系统性红斑狼疮(SLE)是一种多器官受累的复杂自身免疫性疾病,死亡率很高,由于最广泛和经典的免疫抑制治疗而降低。然而,一些患者的死亡率仍然很高。因此,需要改变 SLE 的治疗方法。在过去十年中,大多数移植都是用同种异体或自体造血干细胞治疗 SLE,目前新兴的是间充质干细胞。这两种方法有一些重要的区别。